AimingMed Secures Tens of Millions in Pre-A Financing to Advance High-Throughput and Fully Automated Organoid Platforms

VCBeat has learned that AIMINGMED, an organoid company, recently announced the completion of its Pre-A financing round, raising tens of millions of RMB. This marks AIMINGMED’s second financing round within a year, with the cumulative total from both rounds approaching 100 million RMB. The current round was led by a prominent strategic investor, with participation from Hangzhou Wanlun Shangde Investment Partnership (Limited Partnership) and PURPLE COW STARTUPS. Existing shareholder Vision Capital increased its investment, and Bairong Capital served as the financial advisor. The proceeds from this financing will further accelerate the R&D, market promotion, and team building for the company’s high-throughput and fully automated innovative product portfolio.

AIMINGMED, established in 2020, is an R&D-driven medical technology company centered on organoid technology. Its core team currently comprises experts from top-tier research institutions and clinical centers, including the National University of Singapore, Yale University, the Chinese Academy of Sciences, and West China Hospital. Leveraging its proprietary organoid technology and addressing critical clinical needs, the company is developing fully automated, digital solutions for high-throughput equipment and consumables across the entire workflow of organoid-based drug sensitivity testing.

The company’s core products include the OSCAR automated organoid processing and analysis system, the Signoid organoid-on-a-chip platform, and the Digituor digital organoid solution. Leveraging organoid technology, the company provides an integrated suite of solutions for patients, clinicians, and researchers across scenarios such as precision medication testing for tumor patients, innovative biomedical research, and new drug screening for pharmaceutical companies, ultimately fulfilling its corporate mission: “To give direction to treatment and hope to life.”

For this round of financing,AIMINGMEDDr. You Mingliang, FounderHe stated, “We are grateful for the investors’ recognition of AIMINGMED’s medical endeavors. Organoid technology is a foundational technology with significant growth potential and broad application scenarios. Organoid models can enhance the efficiency of bench-to-bedside translation, guide more precise clinical medication, improve disease control and prognosis, and alleviate the financial burden on cancer patients. AIMINGMED is committed to achieving independent research and development of both high-throughput equipment and consumables, thereby delivering high-quality, cost-effective services to our clients.”

Investors in This RoundWanlun ShangdeHe stated, “We are delighted to participate in this round of financing for AIMINGMED. Wanlun Shangde primarily focuses on early-stage investments, placing significant emphasis on the founding team and the future growth potential of their respective fields. The founding team of AIMINGMED is currently the most multidisciplinary team in the organoid sector, excelling in scientific research, product translation, and medical promotion. Furthermore, we are highly optimistic about the application prospects of organoids as an innovative in vitro model. Research and products in this field, both domestically and internationally, have developed rapidly over the past two years. Meanwhile, national science, technology, and industrial policies are increasingly directed toward and supporting this area. In the future, organoids are poised to deliver breakthrough solutions in innovative drug screening and clinical personalized precision medicine.”

Investors in This RoundDr. Yu Bo, Healthcare Partner at PURPLE COW STARTUPS“We are deeply honored to participate in this round of financing for AIMINGMED. PURPLE COW STARTUPS has long been bullish on foundational platform technologies in precision medicine and regenerative medicine. Human-derived organoid technology is one of the most cutting-edge bioengineering technologies available today, offering significant advantages over existing biological models in mapping in vivo physiological and pathological environments. In the future, it will play a crucial role in drug development, basic research, and personalized diagnosis and treatment, leveraging its strengths in recapitulating in vivo responses as well as cost and throughput efficiency. AIMINGMED is a rare company in China capable of independent R&D across the entire industry chain, from upstream to downstream. By building its own digital tumor organoid models, the company has laid a solid foundation of tools and data to enable scalable replication of downstream organoid services. We hope that under the leadership of Dr. You Mingliang and the founding team, the company will rapidly grow into an industry leader in this field.”

Angel InvestorVision CapitalHe stated, “In the era of national health for all, personalized cancer therapy represents a significant milestone in the development of precision medicine. Patient-derived organoid models can highly simulate the tumor microenvironment in patients, providing a robust theoretical foundation for novel oncology drug development and stratified patient treatment. Meanwhile, their advantages of higher throughput and lower costs have lowered the barrier to entry for organoid-based experiments. AIMINGMED possesses independently developed, full-chain organoid products covering instruments, reagents, and digital tumor model libraries, demonstrating strong service capabilities. We hope that AIMINGMED will rapidly expand its service network, accumulate real-world data on tumor organoids, emerge as an industry leader, and contribute to the future of precision cancer treatment.”

Hangzhou Wanlun Shangde Investment Partnership (Limited Partnership) was established on May 19, 2016. Wanlun Shangde is committed to providing one-stop capital support and services to high-quality life science enterprises in China, building a collaborative ecosystem for the biopharmaceutical and general health industry clusters, and facilitating the high-quality development of its partner companies.

Purple Cow Startups is an early-stage equity investment fund co-founded in 2016 by Fu Sheng, Chairman of Cheetah Mobile, and Zhang Quanling, a former renowned CCTV host. It currently manages two RMB-denominated funds. The firm primarily invests in the healthcare, consumer, and education sectors. Its mission is to identify “purple cows” at emerging market inflection points, leveraging technology and business innovation to address critical societal challenges. Purple Cow Startups seeks out high-potential early-stage ventures, with investments spanning from the angel round to Series A. Purple Cow Healthcare focuses on discovering innovative business models driven by essential clinical needs and technological breakthroughs, concentrating on novel diagnostic and therapeutic solutions for three major disease areas: malignant tumors, cardiovascular and cerebrovascular diseases, and infectious diseases.

Vision Capital, founded in 2015 by Mr. Wu Yongming, co-founder of Alibaba Group, comprises experts from core positions at leading internet companies and seasoned investors from top-tier Chinese venture capital firms, providing startups with practical experience and team support. Vision Capital focuses on investments in new consumption, enterprise services, digital health, and frontier technologies, having invested in over 100 innovative enterprises. In the future, Vision Capital will continue to deepen its engagement in digital health, healthcare services, biotechnology, and medical devices.

Bairong Capital is a research-oriented financial advisory firm focused on the healthcare and medical sector. It aims to facilitate the rapid growth of medical enterprises through its extensive transaction experience, while providing investment institutions with insights into valuable investment opportunities through rigorous and in-depth research. Bairong Capital’s areas of focus span multiple healthcare sub-sectors, including medical services, medical devices and consumables, in vitro diagnostics (IVD) and precision medicine, biopharmaceuticals, and healthcare informatics. The firm’s core team members come from top-tier consulting firms, leading investment banks, and major accounting firms.